TY - JOUR
TI - Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy
AU - Ziogas, D.E.
AU - Spiliotis, J.
AU - Lykoudis, E.G.
AU - Zografos, G.C.
AU - Roukos, D.H.
JO - Future Oncology
PY - 2017
VL - 13
TODO - 2
SP - 113-116
PB - Future Medicine Ltd
SN - 1479-6694, 1744-8301
TODO - 10.2217/fon-2016-0307
TODO - complementary DNA;  trastuzumab;  trastuzumab emtansine, breast cancer;  cancer therapy;  gene mutation;  gene sequence;  genetic heterogeneity;  genetic variability;  human;  metastasis;  next generation sequencing;  overall survival;  priority journal;  Review;  translational research;  Breast Neoplasms;  disease course;  female;  genetic heterogeneity;  genetics;  genomics;  high throughput sequencing;  metabolism;  multimodality cancer therapy;  pathology;  personalized medicine;  procedures;  tumor embolism, Breast Neoplasms;  Combined Modality Therapy;  Disease Progression;  Female;  Genetic Heterogeneity;  Genomics;  High-Throughput Nucleotide Sequencing;  Humans;  Neoplastic Cells, Circulating;  Precision Medicine
TODO - null
ER -